ESC 2016 - PACE-CME

Episodes 17-19 of 19

Inflammation as potential target for therapy to target residual risk post ACS
Inflammation as potential target for therapy to target residual risk post ACS
ESC 2016
Inflammation as potential target for therapy to target residual risk post ACS
- Paul M Ridker, MD
PCSK9, the short track road from discovery as drug target towards the clinic
PCSK9, the short track road from discovery as drug target towards the clinic
ESC 2016
PCSK9, the short track road from discovery as drug target towards the clinic
- Gilles Lambert, MD
Understanding why patients do not take their medication and stimulating adherence
Understanding why patients do not take their medication and stimulating adherence
CSI 2016 ESC
Understanding why patients do not take their medication and stimulating adherence
- Prof. Robert Horne

Previous
1
2
Next

2/2